Coral Genomics
Coral Genomics is a privately held San Francisco-based company founded in 2018 that develops clinical tests to help healthcare providers streamline prior authorization and select effective medications. It operates at an early stage with 1–10 employees.
- Company typePrivate
- Founded2025
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Coral Genomics does
Coral Genomics is a privately held, for-profit company headquartered in San Francisco, California, founded in 2018. The company develops clinical tests intended to help healthcare providers streamline the prior authorization process and select effective medications for patients. Its offering sits at the intersection of genomics-based diagnostics and clinical workflow automation, targeting two tightly coupled pain points in U.S. healthcare delivery: payer prior authorization friction and therapy selection.
The company is led by co-founder and CEO Atray Dixit and Chief Scientific Officer Kasey Davis, and operates with a lean team of 1–10 employees. To date, Coral Genomics has assembled approximately $5.7 million in capital, the majority of which is non-dilutive grant funding — a $2.0 million award from the National Human Genome Research Institute (NHGRI) in October 2020 and a $1.7 million award from the National Institutes of Health (NIH) in January 2021 — supplemented by a $2.0 million seed equity round in 2019 led by 8VC, Soma Capital, and Y Combinator. The grant-heavy capital structure is consistent with a pre-commercial R&D posture rather than a scaled go-to-market motion.
No information is disclosed regarding specific product SKUs, pricing, payer contracts, provider customers, regulatory clearances, partnerships, or revenue. This data gap constrains any deeper commercial or competitive assessment; the company should be treated as an early-stage, R&D-oriented entity whose commercial profile has not yet been validated in the available record.
Coral Genomics firmographics
Firmographics- Name
- Coral Genomics
- Legal name
- JANJI33
- Website
- https://coralgenomics.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Coral Genomics is a privately held San Francisco-based company founded in 2018 that develops clinical tests to help healthcare providers streamline prior authorization and select effective medications. It operates at an early stage with 1–10 employees.
- Ownership category
- akta.pro rank
Coral Genomics industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Coral Genomics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Coral Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Coral Genomics product offering
Product offeringCore offering
Coral develops new clinical tests that help healthcare providers streamline prior authorization and select the effective medication for patients. The offering combines genomics-based testing with clinical decision support functionality to reduce administrative friction and improve prescribing accuracy for provider organizations.
Differentiator
Problem solved
Functional benefit
Products and services
- Coral Clinical Tests A genomics-based clinical test offering that helps healthcare providers streamline the prior authorization process and select the most effective medication for patients. Targeted at provider organizations (hospitals, clinics, group practices) seeking to reduce administrative friction and improve prescribing accuracy.
Companies that use Coral Genomics
Customer profileIdeal customer profiles1 record
Coral Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Coral Genomics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Coral Genomics competitors and assessment
Company assessmentDirect peers
- Molecular Health: Provides clinical decision support software that analyzes a patient's genomic and clinical data to guide drug selection and avoid adverse events — directly comparable to Coral's medication-selection positioning.
- Color Health: Operates a clinical-grade genetic testing platform that returns results integrated into provider workflows, with employer and payer partnerships — comparable clinical-genomics infrastructure and GTM model.
- Helix: Clinical DNA sequencing platform with an integrated population-health and pharmacogenomics pipeline; comparable as a sequencing-enabled clinical testing company serving providers and payers.
- Genomind: Pharmacogenomic testing company focused on mental health medication selection and response prediction — closely comparable to Coral's medication-selection positioning within a specific therapeutic area.
Broad incumbents
- Tempus AI: Large precision medicine company offering molecular testing and clinical decision support across oncology and other therapeutic areas — overlaps with Coral's biomarker-driven drug selection thesis but at much broader scale.
- Myriad Genetics: Established clinical genetic testing company with reimbursed pharmacogenomic and disease-risk tests — comparable end market (providers/payers) and test-driven revenue model, but with a much broader menu.
- Foundation Medicine: Roche-owned provider of comprehensive genomic profiling tests whose results guide therapy selection, particularly in oncology — comparable as evidence-based testing informing drug choice.
Emerging players
- CoverMyMeds: McKesson-owned prior authorization automation platform widely used by U.S. providers and pharmacies — adjacent rather than direct, since it does not run the lab tests themselves, but represents the workflow Coral would integrate with.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Coral Genomics social profiles
Digital presenceCoral Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coral Genomics leadership team
Management profileNumber of profiles
Profiles2 records
Coral Genomics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coral Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coral Genomics
What does Coral Genomics do?
Coral develops new clinical tests that help healthcare providers streamline prior authorization and select the effective medication for patients. The offering combines genomics-based testing with clinical decision support functionality to reduce administrative friction and improve prescribing accuracy for provider organizations.
Is Coral Genomics a public or private company?
Coral Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Coral Genomics founded?
Coral Genomics was founded in 2025. It employs 1 to 10 people.
Where is Coral Genomics based?
Coral Genomics is headquartered in San Francisco, United States, in the North America region.
Who are Coral Genomics's main competitors?
Direct peers on record are Molecular Health, Color Health, Helix and Genomind. Broad incumbents are Tempus AI, Myriad Genetics and Foundation Medicine. CoverMyMeds is listed as an emerging player.
Does Coral Genomics have an API?
No public API is recorded for Coral Genomics.
What industry is Coral Genomics in?
Coral Genomics's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.